RU2490279C2 - Композиции глюкана - Google Patents
Композиции глюкана Download PDFInfo
- Publication number
- RU2490279C2 RU2490279C2 RU2009101051/10A RU2009101051A RU2490279C2 RU 2490279 C2 RU2490279 C2 RU 2490279C2 RU 2009101051/10 A RU2009101051/10 A RU 2009101051/10A RU 2009101051 A RU2009101051 A RU 2009101051A RU 2490279 C2 RU2490279 C2 RU 2490279C2
- Authority
- RU
- Russia
- Prior art keywords
- glucan
- soluble
- unmodified
- composition
- molecular weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 229920001503 Glucan Polymers 0.000 title description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 116
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 37
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 6
- 150000002402 hexoses Chemical class 0.000 claims description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 23
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- 238000005119 centrifugation Methods 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 2
- 238000003825 pressing Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- 238000000605 extraction Methods 0.000 description 15
- 239000012535 impurity Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000012855 volatile organic compound Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 210000005253 yeast cell Anatomy 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- -1 folic acid Natural products 0.000 description 10
- 239000003513 alkali Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 238000005227 gel permeation chromatography Methods 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002518 antifoaming agent Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920000057 Mannan Polymers 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
- 239000002198 insoluble material Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 244000288561 Torulaspora delbrueckii Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 230000002435 cytoreductive effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000383 hazardous chemical Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- FIHZWZBEAXASKA-UHFFFAOYSA-N Anthron Natural products COc1cc2Cc3cc(C)cc(O)c3C(=O)c2c(O)c1C=CC(C)C FIHZWZBEAXASKA-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000356408 Candida cloacae Species 0.000 description 1
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241001489198 Cyberlindnera americana Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 241001042096 Cyberlindnera tropicalis Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000125500 Hedypnois rhagadioloides Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000125026 Humbertiella henrici Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001480034 Kodamaea ohmeri Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241001304302 Kuraishia capsulata Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000299657 Preussia polymorpha Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241001489220 Vanderwaltozyma polyspora Species 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical class [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- CGPVLUCOFNAVGV-UHFFFAOYSA-N copper;pentahydrate Chemical compound O.O.O.O.O.[Cu] CGPVLUCOFNAVGV-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- IZEMHEXSGIOXDA-UHFFFAOYSA-N iron;hexahydrate Chemical compound O.O.O.O.O.O.[Fe] IZEMHEXSGIOXDA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000002103 osmometry Methods 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81397106P | 2006-06-15 | 2006-06-15 | |
| US60/813,971 | 2006-06-15 | ||
| PCT/US2007/014055 WO2007146416A2 (en) | 2006-06-15 | 2007-06-15 | Glucan preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009101051A RU2009101051A (ru) | 2010-07-20 |
| RU2490279C2 true RU2490279C2 (ru) | 2013-08-20 |
Family
ID=38832560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009101051/10A RU2490279C2 (ru) | 2006-06-15 | 2007-06-15 | Композиции глюкана |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9610303B2 (enExample) |
| EP (1) | EP2032180B1 (enExample) |
| JP (3) | JP2009540106A (enExample) |
| CN (2) | CN103833867B (enExample) |
| BR (1) | BRPI0713734A2 (enExample) |
| CA (1) | CA2655414C (enExample) |
| ES (1) | ES2628021T3 (enExample) |
| IL (2) | IL195937A (enExample) |
| MX (1) | MX2008016039A (enExample) |
| RU (1) | RU2490279C2 (enExample) |
| WO (2) | WO2007146416A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO20014256D0 (no) * | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Fremstilling av immunstimulerende forbindelse |
| US7514085B2 (en) * | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
| US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
| EP1896601A1 (en) * | 2005-06-15 | 2008-03-12 | Medimush A/S | Bioactive agents produced by submerged cultivation of a basidiomycete cell |
| WO2007146416A2 (en) | 2006-06-15 | 2007-12-21 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Glucan preparations |
| US20080167268A1 (en) * | 2006-09-01 | 2008-07-10 | Jun Yan | Particulate beta-glucan compositions for regulating dendritic cells |
| WO2008027581A1 (en) * | 2006-09-01 | 2008-03-06 | University Of Louisville | Mcrp antagonists and their uses |
| CN101407559B (zh) * | 2008-11-25 | 2011-01-26 | 天津科技大学 | 一种快速制备酵母β-1,3-葡聚糖的方法 |
| FI20080665A0 (fi) * | 2008-12-18 | 2008-12-18 | Glykos Finland Oy | Luonnollisen tyyppiset sakkaridikoostumukset |
| JP5172930B2 (ja) * | 2009-10-20 | 2013-03-27 | 国立大学法人佐賀大学 | 高粘性培養液の粘性低下方法 |
| US9943607B2 (en) | 2011-05-09 | 2018-04-17 | Biothera, Inc. | Beta-glucan compounds, compositions, and methods |
| EP2714053B1 (en) | 2011-06-03 | 2020-12-09 | Hibercell, Inc. | Opsonized beta-glucan preparations and methods |
| HK1205466A1 (en) | 2012-02-22 | 2015-12-18 | Algal Scientific Corporation | Animal feed compositions and methods of using the same |
| CA2872010C (en) | 2012-04-30 | 2021-06-08 | Biothera, Inc. | Compositions and methods for .beta.-glucan immunotherapy |
| WO2015084732A1 (en) | 2013-12-05 | 2015-06-11 | Biothera, Inc. | β-GLUCAN ASSAY METHODS |
| LT6145B (lt) | 2014-04-14 | 2015-04-27 | Uab "Biocentras" | TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ |
| EP3166616B1 (en) | 2014-07-10 | 2021-04-07 | Biothera, Inc. | Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment |
| ES2875338T3 (es) | 2014-11-06 | 2021-11-10 | Hibercell Inc | Métodos de beta-glucano y composiciones que afectan al microentorno tumoral |
| MY181390A (en) | 2014-11-19 | 2020-12-21 | Tablemark Co Ltd | Flavor improvement method for yeast cells and food quality imrproving agent |
| JP2016208909A (ja) * | 2015-05-08 | 2016-12-15 | 株式会社カネカ | 脂溶性生理活性物質の製造方法 |
| JP6935877B2 (ja) * | 2017-01-27 | 2021-09-15 | 日本製紙株式会社 | 免疫調整剤 |
| US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
| MX2020009510A (es) | 2018-03-13 | 2021-08-05 | Hibercell Inc | Inmunoterapia combinada de beta glucano y agonista cd40. |
| JP6530846B1 (ja) * | 2018-10-09 | 2019-06-12 | アサヒグループホールディングス株式会社 | 免疫賦活剤及び感染予防方法 |
| US11140912B1 (en) | 2020-12-22 | 2021-10-12 | Agvault, Llc | Process for manufacturing yeast strains having increased mannan oligosaccharides and improved amino acid profiles |
| WO2023107712A1 (en) | 2021-12-10 | 2023-06-15 | Hibercell, Inc. | SOLUBLE β-GLUCANS FOR INDUCING TRAINED IMMUNITY |
| CN115028755B (zh) * | 2022-07-01 | 2023-08-11 | 福建省农业科学院食用菌研究所 | 一种高分子量绣球菌β-葡聚糖的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143883A (en) * | 1998-12-31 | 2000-11-07 | Marlyn Nutraceuticals, Inc. | Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system |
| RU2233599C2 (ru) * | 1998-10-26 | 2004-08-10 | Себа Аб | СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ВОДОРАСТВОРИМЫЙ β-ГЛЮКАН, (ВАРИАНТЫ) И ИЗГОТАВЛИВАЕМЫЕ ИЗ НЕЕ ПРОДУКТЫ |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082936A (en) | 1984-11-28 | 1992-01-21 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
| US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
| US5250436A (en) | 1984-11-28 | 1993-10-05 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
| US4962094A (en) | 1988-10-28 | 1990-10-09 | Alpha Beta Technology, Inc. | Glucan dietary additives |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| JPH05502018A (ja) | 1989-09-08 | 1993-04-15 | アルファ ベータ テクノロジー，インコーポレイティッド | 免疫系活性化方法 |
| US5622939A (en) | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
| JPH05503952A (ja) | 1989-09-08 | 1993-06-24 | アルファ ベータ テクノロジー，インコーポレイティッド | 可溶性グルカン類の製造方法 |
| US5811542A (en) * | 1989-09-08 | 1998-09-22 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
| US5488040A (en) | 1989-09-08 | 1996-01-30 | Alpha-Beta Technology, Inc. | Use of neutral soluble glucan preparations to stimulate platelet production |
| US6143731A (en) | 1989-10-20 | 2000-11-07 | The Collaborative Group, Ltd. | Glucan dietary additives |
| US6020324A (en) | 1989-10-20 | 2000-02-01 | The Collaborative Group, Ltd. | Glucan dietary additives |
| US5223491A (en) * | 1989-11-09 | 1993-06-29 | Donzis Byron A | Method for revitalizing skin by applying topically water insoluble glucan |
| JP2547220Y2 (ja) | 1990-07-19 | 1997-09-10 | 株式会社ユニシアジェックス | アクチュエータ |
| US5519009A (en) | 1993-10-01 | 1996-05-21 | Donzis; Byron A. | Solubilized yeast glucan |
| US5622940A (en) * | 1994-07-14 | 1997-04-22 | Alpha-Beta Technology | Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan |
| US5576015A (en) | 1995-03-02 | 1996-11-19 | Donzis; Byron A. | Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| US6214337B1 (en) | 1995-04-18 | 2001-04-10 | Biotec Asa | Animal feeds comprising yeast glucan |
| US6117850A (en) | 1995-08-28 | 2000-09-12 | The Collaborative Group, Ltd. | Mobilization of peripheral blood precursor cells by β(1,3)-glucan |
| US6110692A (en) | 1996-05-01 | 2000-08-29 | The Collaborative Group, Ltd. | Receptor for underivatized aqueous soluble β(1-3)-glucan |
| US6084092A (en) * | 1997-01-31 | 2000-07-04 | The Collaborative Group, Ltd. | β(1-3)-glucan diagnostic assays |
| US6090938A (en) * | 1996-05-01 | 2000-07-18 | Collaborative Group, Ltd. | Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan |
| US6413715B2 (en) | 1997-01-31 | 2002-07-02 | The Collaborative Group | β(1-3)-glucan diagnostic assays |
| US6046323A (en) | 1997-07-29 | 2000-04-04 | The Collaborative Group, Ltd. | Conformations of PPG-glucan |
| AU6261999A (en) | 1998-09-25 | 2000-04-17 | Collaborative Group, Ltd., The | Very high molecular weight beta-glucans |
| US6369216B1 (en) * | 1998-09-25 | 2002-04-09 | Biopolymer Engineering Pharmaceutical, Inc. | Very high molecular weight β-glucans |
| JP2001342257A (ja) * | 2000-06-01 | 2001-12-11 | Fuji Photo Film Co Ltd | セルロース系ポリマーの製造方法 |
| JP2002105101A (ja) * | 2000-10-03 | 2002-04-10 | Ajinomoto Co Inc | 水溶性高分子の製造法 |
| US7786094B2 (en) | 2001-10-09 | 2010-08-31 | Biopolymer Engineering, Inc. | Use of beta-glucans against biological warfare weapons and pathogens including anthrax |
| US20070042930A1 (en) | 2002-08-13 | 2007-02-22 | Ross Gordon D | Effect of beta-glucan on stem cell recruitment and tissue repair |
| EP1545208A4 (en) | 2002-08-13 | 2006-04-12 | Biopolymer Engineering Inc | METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT |
| US20060165700A1 (en) | 2002-09-04 | 2006-07-27 | Ostroff Gary R | Cancer therapy using whole glucan particles and antibodies |
| CN1694715B (zh) | 2002-09-04 | 2010-12-01 | 路易斯维尔大学研究基金会 | β葡聚糖和抗体在制备治疗癌性的药物中的用途 |
| CA2501820C (en) * | 2002-10-08 | 2009-12-15 | Ricom Corporation | Chitosan-containing polysaccharide, method for preparing the same and use thereof |
| EP1721990B1 (en) * | 2004-02-13 | 2009-03-18 | Alpron Co., Ltd | Process for producing yeast-derived glucan |
| WO2006085895A2 (en) | 2004-05-10 | 2006-08-17 | Biopolymer Engineering, Inc. | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies |
| GB0411880D0 (en) | 2004-05-27 | 2004-06-30 | Imagination Tech Ltd | Method and apparatus for efficient evaluation of "table-based" mathematical functions |
| FI20040804A7 (fi) * | 2004-06-11 | 2005-12-12 | Cerefract Oy | Menetelmä viljan ainesosan erottamiseksi |
| US20050020490A1 (en) * | 2004-10-18 | 2005-01-27 | Progressive Bioactives Incorporated | A Method of Producing an Economical and Ecologically Sound Natural Immunobiotic Extract for Use as a Health Management Instrument and a Replacement for Growth Promotion Antibiotics in Livestock and Companion Animals. |
| EP1917019A2 (en) | 2005-05-03 | 2008-05-07 | Biopolymer Engineering, Inc. | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
| KR20080106160A (ko) | 2005-11-01 | 2008-12-04 | 씨피 켈코 유에스, 인코포레이티드 | 변성 카르복시메틸셀룰로오스 물질로 제조된 필름 및 캡슐및 그의 제조방법 |
| WO2007146417A2 (en) | 2006-06-15 | 2007-12-21 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity |
| WO2007146416A2 (en) | 2006-06-15 | 2007-12-21 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Glucan preparations |
| US20080167268A1 (en) | 2006-09-01 | 2008-07-10 | Jun Yan | Particulate beta-glucan compositions for regulating dendritic cells |
| WO2008027581A1 (en) | 2006-09-01 | 2008-03-06 | University Of Louisville | Mcrp antagonists and their uses |
| EP2146744A4 (en) | 2007-04-24 | 2012-07-25 | Univ Louisville Res Found | THERAPEUTIC BETA-GLUCAN COMPOSITIONS |
| UA101617C2 (ru) | 2007-05-08 | 2013-04-25 | Байополимер Инджиниринг, Инк. Дба Байотера, Инк. | Способ получения растворимого бета-глюкана |
| EP2200736B1 (de) | 2007-10-08 | 2016-11-30 | Basf Se | Verfahren zur herstellung von formkörpern mit katalytischen eigenschaften als reaktoreinbauten |
-
2007
- 2007-06-15 WO PCT/US2007/014055 patent/WO2007146416A2/en not_active Ceased
- 2007-06-15 CN CN201310718360.0A patent/CN103833867B/zh not_active Expired - Fee Related
- 2007-06-15 EP EP07796157.1A patent/EP2032180B1/en active Active
- 2007-06-15 CN CN200780029944.XA patent/CN101553261B/zh not_active Expired - Fee Related
- 2007-06-15 MX MX2008016039A patent/MX2008016039A/es active IP Right Grant
- 2007-06-15 JP JP2009515512A patent/JP2009540106A/ja active Pending
- 2007-06-15 CA CA2655414A patent/CA2655414C/en active Active
- 2007-06-15 ES ES07796157.1T patent/ES2628021T3/es active Active
- 2007-06-15 US US11/818,741 patent/US9610303B2/en active Active
- 2007-06-15 WO PCT/US2007/014191 patent/WO2007146440A2/en not_active Ceased
- 2007-06-15 RU RU2009101051/10A patent/RU2490279C2/ru active
- 2007-06-15 US US11/818,804 patent/US20080108114A1/en not_active Abandoned
- 2007-06-15 BR BRPI0713734-6A patent/BRPI0713734A2/pt not_active Application Discontinuation
-
2008
- 2008-12-15 IL IL195937A patent/IL195937A/en active IP Right Grant
-
2013
- 2013-11-01 JP JP2013228688A patent/JP5851472B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-22 IL IL236842A patent/IL236842A/en active IP Right Grant
- 2015-12-02 JP JP2015235912A patent/JP6196280B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-21 US US15/437,778 patent/US10272101B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233599C2 (ru) * | 1998-10-26 | 2004-08-10 | Себа Аб | СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ВОДОРАСТВОРИМЫЙ β-ГЛЮКАН, (ВАРИАНТЫ) И ИЗГОТАВЛИВАЕМЫЕ ИЗ НЕЕ ПРОДУКТЫ |
| US6143883A (en) * | 1998-12-31 | 2000-11-07 | Marlyn Nutraceuticals, Inc. | Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system |
Non-Patent Citations (2)
| Title |
|---|
| BACON J.S. ET AL. The glucan components of the cell wall of baker's yeast (Saccharomyces cerevisiae) considered in relation to its ultrastructure// Biochem J. 1969 Sep, v.114, №3, p.557-567. * |
| HUNTER K.V. ET AL. Preparation of microparticulate beta-glucan from Saccharomyces cerevisiae for use in immune potentiation. Lett Appi Microbiol. 2002, v.35, №4, p.267-271. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2490279C2 (ru) | Композиции глюкана | |
| JP2832551B2 (ja) | アロエ製品の製造方法 | |
| EP2666779A1 (en) | Method for mass preparation of proteoglycan | |
| WO2023036203A1 (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
| JP2022545594A (ja) | 水溶性アスタキサンチン複合体の調製方法及びそれにより調製されたアスタキサンチン水溶液 | |
| Ain et al. | Fabrication of mesoporous silica nanoparticles for releasable delivery of licorice polysaccharide at the acne site in topical application | |
| CN1363611A (zh) | 黄精多糖的提取方法及其用途 | |
| AU2014201427B2 (en) | Glucan preparations | |
| CN110218263B (zh) | 一种猴头菇菌糠多糖、制备方法及应用 | |
| AU2007258191B2 (en) | Glucan preparations | |
| BE1027863A1 (fr) | Une inuline de farine de helianthus tuberosus (L. 1753) L. pour améliorer la dyspepsie fonctionnelle et un procédé de préparation et une utilisation de celle-ci | |
| CN118290603A (zh) | 一种抗幽门螺杆菌海参肠岩藻多糖及其制备方法与应用 | |
| HK1138215B (en) | Glucan preparations | |
| CN117363671A (zh) | 一种发酵提高海参肠多糖提取率及生物活性的方法 | |
| JP7312485B2 (ja) | アディポネクチン分泌促進剤 | |
| JPH07228601A (ja) | 水溶性β−１，３−グルカン誘導体及びそれを含む抗ウイルス剤 | |
| CN114410375B (zh) | 一种粗羊毛脂的精炼方法 | |
| CN1464050A (zh) | 用新鲜动物血提取超氧化物岐化酶的方法 | |
| TW202410907A (zh) | Cs-4發酵菌絲體雜聚多醣及其製備方法與用途 | |
| CN115838441A (zh) | 一种黄刺多糖bdp-i（b）的制备方法 | |
| SK285062B6 (sk) | Spôsob prípravy beta-1,3/1,6(1,4)-glukánu z hlivy ustricovitej (Pleurotus ostreatus) | |
| BE888635A (fr) | Nouvel extrait de plante, procede de preparation, agent immunostimulant comprenant cet extrait comme composant efficace et immunotherapie par son utilisation, | |
| FR2631976A1 (fr) | Polyglycannes hydrosolubles possedant notamment des proprietes viscosantes | |
| CN107670008A (zh) | 生姜消毒剂的制备方法 |